Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.3 (
phospholipase C
)
18,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
High concentrations of novel, haloperidol- and DTG-inaccessible (+)-[3H]-3-
PPP
binding sites were found in human peripheral blood leukocytes rat spleen and splenocytes, but not in rat brain. Splenic sites were localized in a course punctate pattern in the marginal zones and red pulp. The pharmacology of the splenic sites was: (-)-SKF 10,047 > or = naltrexone = (-)-pentazocine > (+)-pentazocine = (-)-3-
PPP
= (+)-SKF 10,047 > or = (+)-3-
PPP
> or = dextrorphan > dextromethorphan > PCP > clorgyline. DTG, haloperidol, TCP, (-)-deprenyl and SKF 525-A did not complete. Binding activity was destroyed by heating and
phospholipase C
, but not by proteases or glycosidases. These sites may be involved in immunomodulation by opiate and sigma receptor agonists.
...
PMID:Initial characterization and autoradiographic localization of a novel sigma/opioid binding site in immune tissues. 876 30